A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

Authors

Mark A. Schroeder, Washington University School of Medicine in St. Louis
Karl Staser, Washington University School of Medicine in St. Louis
Jaebok Choi, Washington University School of Medicine in St. Louis
Leah Gehrs, Washington University School of Medicine in St. Louis
John F. DiPersio, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2020

Volume

4

Issue

8

First Page

1656

Last Page

1669

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019001043

Rights and Permissions

Mark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, Leah Gehrs, Michael C. Arbushites, Ying Yan, Peter Langmuir, Nithya Srinivas, Michael Pratta, Miguel-Angel Perales, Yi-Bin Chen, Gabrielle Meyers, John F. DiPersio; A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv 2020; 4 (8): 1656–1669. doi: https://doi.org/10.1182/bloodadvances.2019001043

Recommended Citation

Schroeder, Mark A.; Staser, Karl; Choi, Jaebok; Gehrs, Leah; DiPersio, John F.; and al., et, "A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease." Blood Advances. 4, 8. 1656 - 1669. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9303